During the third quarter, Lee Financial Co initiated a position in UnitedHealth Group by acquiring 3,390 shares valued at approximately $1.17 million, according to its latest Form 13F filing. Brighton Jones LLC more than doubled its exposure, increasing its holdings by 176.2% to 44,249 shares (worth $22.38 million) after adding 28,231 shares in the fourth quarter. Revolve Wealth Partners LLC raised its stake by 137.1%, bringing its total to 4,019 shares (about $2.03 million) following a 2,324-share purchase. Several smaller institutions also made moves: CMT Capital Markets Trading GmbH established a new $340,000 stake in Q2, Patriot Financial Group Insurance Agency boosted its holding by 42.5% to 5,312 shares ($1.66 million), and Montz Harcus Wealth Management added 74 shares for a 12.2% increase to 679 shares ($212,000). Overall, hedge funds and institutional investors now control 87.86% of the company’s outstanding shares.

In its fourth-quarter release, UnitedHealth Group reported adjusted earnings per share of $2.11, surpassing consensus forecasts by $0.02. Quarterly revenue reached $113.22 billion, falling short of the Wall Street consensus by $160 million. The company achieved a net margin of 2.69% and a return on equity of 14.79%, while revenue grew 12.3% year-over-year. Notably, EPS of $6.81 in the same quarter last year underscores a sequential normalization as the prior period included one-time items. Management highlighted continued strength in both UnitedHealthcare and Optum platforms, with membership growth exceeding expectations in commercial employer-sponsored plans.

UnitedHealth Group set full-year 2026 earnings guidance at $17.75 per share, below the consensus estimate of $29.54, reflecting anticipated headwinds in benefit cost trends and slower volume growth in certain care delivery segments. Following the outlook, Jefferies lowered its target to $340 and maintained a buy rating, while Oppenheimer trimmed its objective to $385 but upheld an outperform view. KeyCorp and TD Cowen retained overweight and hold ratings respectively, with TD Cowen nudging its target modestly upward to $338. MarketBeat data indicates a consensus “Moderate Buy” stance, with 17 buy recommendations, nine holds and two sells.

As of the end of Q4, the company’s debt-to-equity ratio stood at 0.72, and liquidity metrics included a quick ratio of 0.82 and a current ratio of 0.79, reflecting a balanced capital structure. UnitedHealth maintained a dividend policy with a quarterly payout of $2.21 per share, equating to an annualized yield of 3.1% and a payout ratio of 67.02%. The board’s commitment to returning capital is further evidenced by consistent increases in dividend distributions over the past five years, supported by robust free cash flow generation across both operating segments.